• Have a question?
    Open from 8am to 7pm Monday to Friday    Call customer services
    0345 54 32 600


| Print

NANOBIOTIX (NANO)

NANOBIOTIX
Sell: €27.76|Buy: €28.00|Change: 1.52 (5.77%)

This share can be held in a Dealing accountStocks and shares ISALifetime ISAJISASIPP

Company profile

Nanobiotix SA is a late-stage clinical biotechnology company focused on re-inventing medicine by building new therapies atom by atom, developing widely applicable, first-in-class, physics-based nanotherapeutics to transform treatment outcomes and expand life for millions of patients. The objective of this physics-based approach is to allow nanoparticles to be combined with other drugs or therapeutic modalities and to integrate seamlessly into clinical practice without addingburden for the patient, healthcare provider, or healthcare system. It has three platforms Nanoradioenhancer platform: Nanoprimer platform: and Neurological disease platform. It has one segment, which is the research and development of product candidates that use proprietary nanotechnology to transform cancer treatment.

Address




Website

https://www.nanobiotix.com

Sector 

Healthcare

Forecast key dates

NameKey Date
Nanobiotix SA Fourth Quarter Earnings Conference Call for 20262027-04-01T08:00:00
Nanobiotix SA Fourth Quarter Earnings Results for 20262027-03-31T00:00:00
Nanobiotix SA Annual Report for 20262027-03-31T00:00:00
Nanobiotix SA Third Quarter Earnings Results for 20262026-11-24T00:00:00
Nanobiotix SA Second Quarter Earnings Results for 20262026-09-30T00:00:00
Nanobiotix SA First Quarter Earnings Results for 20262026-05-21T00:00:00
Nanobiotix SA Annual General Meeting for 20262026-05-19T14:30:00
Nanobiotix SA Fourth Quarter Earnings Conference Call for 20252026-04-01T08:00:00

Previous key dates

NameKey Date
Nanobiotix SA Fourth Quarter Earnings Conference Call for 20252026-04-01T08:00:00
Nanobiotix SA Annual Report for 20252026-03-31T00:00:00
Nanobiotix SA Fourth Quarter Earnings Results for 20252026-03-31T00:00:00
Nanobiotix SA Third Quarter Earnings Results for 20252025-11-24T00:00:00
Jefferies London Healthcare Conference2025-11-17T10:00:00
Nanobiotix SA Second Quarter Earnings Results for 20252025-09-30T00:00:00
New Phase 1 Results In Metastatic Melanoma2025-09-18T08:00:00
H.C. Wainwright 27th Annual Global Investment Conference2025-09-09T09:00:00
Jefferies Global Healthcare Conference2025-06-05T15:45:00
Nanobiotix SA First Quarter Earnings Results for 20252025-05-21T00:00:00
Nanobiotix SA Annual General Meeting for 20252025-05-19T14:30:00
Full Results Phase 1 Pancreas (ESTRO 2025)2025-05-05T08:00:00
Nanobiotix SA Fourth Quarter Earnings Conference Call for 20242025-04-03T08:00:00
Nanobiotix SA Annual Report for 20242025-04-02T00:00:00
Nanobiotix SA Fourth Quarter Earnings Results for 20242025-04-02T00:00:00

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.

© Copyright 2026 AJ Bell. All rights reserved.